Mode
Text Size
Log in / Sign up
N/A Completed N=295

Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients

Source: ClinicalTrials.gov NCT01108809 ↗
Enrolled (actual)
295
Serious AEs
0.3%
Results posted
Sep 2012
Primary outcomePrimary: Change in Systolic Blood Pressure From Baseline to Study End — -39.2 mmHg

Summary

The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risk scores. The study will also evaluate the current antihypertensive treatment pattern in the daily practice among the patient population at increased cardiovascular risk.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Systolic Blood Pressure From Baseline to Study End
-39.2 —
PRIMARY
Change in Diastolic Blood Pressure From Baseline to Study End
-17.8 —
PRIMARY
Evolution of the Cardiovascular Risk Factor SCORE From Baseline to Study End
64.8; 8.8; 0.3; 26.1 —
PRIMARY
Evolution of the Cardiovascular Risk Factor Framingham From Baseline to Study End
58.3; 10.2; 0.3; 31.2 —
PRIMARY
Evolution of the European Society of Hypertension / European Society of Cardiology (ESH/ESC) Based Cardiovascular Risk Factor From Baseline to Study End
65.1; 12.9; 0.3; 21.7 —
SECONDARY
Percentage of Patients That Achieve Target Blood Pressure Values According to the European Society of Hypertension/European Society of Cardiology (ESH/ESC)
57.3 —
SECONDARY
Additional Antihypertensive Treatment Pattern at Visit 3 (End of Study)
16.9; 34.8; 39.3; 75.1; 20.9 —
SECONDARY
Change in Heart Rate From Baseline to Study End
-7.6 —
SECONDARY
Number of Participants Not Completing Study
3; 1 —
SECONDARY
Number of Patients With Adverse Events (AE)
4 —

Eligibility Criteria

Inclusion criteria

  • diagnosis of essential arterial hypertension (BP>140/90 mm HG or BP>130/80 mm Hg for diabetic patients)
  • at least one additional cardiovascular risk factor and/or known single or multiple end organ damage and/or previous cardiovascular disease

Exclusion criteria

  • hypersensitivity to the active substance or to any of the excipients in any ACE inhibitor or angiotensin receptor blocker (ARB) available on the local market, as prescribed in the SPC
  • pregnancy and lactation
  • diseases involving biliary obstruction
  • severe liver impairment
  • severe hypertension
  • malignant hypertension
  • secondary hypertension
  • patients age under 18 years
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01108809). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search